Larimar to kick off higher dose of lead rare disease drug, initiate OLE trial

The FDA gave Larimar Therapeutics the go-ahead to introduce a higher dose of its Friedreich’s ataxia treatment in a Phase II study.

The biotech announced Tuesday that the company can now use 50 mg doses of its lead drug, also known as CTI-1601, in the study. The 12 to 15 adult patients Larimar plans to enroll in that cohort will be randomized to either the drug or placebo, then dosed every day for the first two weeks.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

JURA Bio, Syena partner to develop TCR-based therapies

JURA Bio will use the funding for expediting the mapping of the adaptive immune system. Credit: Cavan Images/Shutterstock.com. JURA Bio has entered a research collaboration

September 22, 2023

Recreational Drug Use More Common in Intensive Cardiac Care Than Many Admit

Many recreational drug users suffering acute cardiovascular events ended up in cardiac intensive care units (ICUs) without disclosing their drug use, according to the ADDICT-ICCU

August 18, 2023

Trastuzumab duocarmazine by Byondis for Gastric Cancer: Likelihood of Approval

Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Gastric Cancer.

February 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.